Drugs / Varivax
Varivax
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00005009 | Feb 1998 → Jun 2001 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00000837 | ? → Nov 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001125 | ? → Mar 2004 | HIV infectious disease, chickenpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04072497 | Nov 2018 → Apr 2020 | herpes zoster | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 1/2 | NCT00258726 | Oct 2005 → Jul 2007 | chickenpox, measles, mumps infectious disease, rubella | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04398706 | May 2020 → Aug 2023 | chickenpox, diphtheria, haemophilus meningitis, hepatitis B virus infection +6 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01049035 | Dec 2009 → Feb 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00546819 | Oct 2007 → Aug 2010 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00505063 | Jul 2007 → Jun 2025 | childhood malignant neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00109122 | Nov 2001 → Feb 2003 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 313 trials · 2 met primary | ||||||
| Phase 3 | NCT07415252 | Jul 2026 → Feb 2027 expected | chickenpox | SK Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03893448 | Jun 2019 → May 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT03843632 | Mar 2019 → Jun 2020 | chickenpox | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01527370 | Oct 2012 → Apr 2013 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01245751 | Apr 2011 → Jul 2012 | herpes zoster | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00871117 | Mar 2009 → Jan 2010 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00534248 | Oct 2007 → Jan 2010 | herpes zoster | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00444860 | Mar → May 2007 | varicella zoster infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00322231 | May 2006 → Jul 2007 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00130793 | Aug → Nov 2005 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00432523 | Jan → Sep 2005 | chickenpox, measles, mumps infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00197015 | Oct 2003 → Jun 2009 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00092417 | Oct 2003 → Jun 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02624375 | Feb 2016 → Nov 2019 | herpes zoster | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT01556451 | Apr → Oct 2012 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00550745 | Sep 2007 → Jan 2009 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00432731 | Dec 2004 → Sep 2005 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04774887 | Nov 2021 → Oct 2023 | HIV infectious disease, human papilloma virus infection | Indiana University | Completed | No outcome recorded |
| — | NCT02590068 | Dec 2015 → Sep 2017 | chronic hepatitis C virus infection | Rockefeller University | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy36 trials | ||||||
| Phase 1 | NCT02367638 Comparator | Mar → Jul 2015 | chickenpox | Green Cross Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03121638 Comparator | Nov 2012 → Feb 2013 | varicella zoster infection | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT06851832 Comparator | Feb 2025 → Sep 2026 overdue | herpes zoster | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05422508 Comparator | Jul 2022 → Jun 2025 overdue | chickenpox | Green Cross Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT05084508 Comparator | Feb 2022 → Feb 2024 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03114982 Comparator | May → Jul 2016 | chickenpox | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00861744 Background | Jun 2009 → Jul 2010 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00134719 Background | Apr 2005 → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT07054099 Comparator | Mar 2026 → Aug 2027 expected | chickenpox | GC Biopharma Corp | Recruiting | No outcome recorded |
| Phase 3 | NCT06975878 Background | May 2025 → Aug 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06855160 Comparator | Apr 2025 → Sep 2026 overdue | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06824181 Background | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06824194 Background | Feb 2025 → Oct 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06736041 Background | Dec 2024 → May 2027 expected | — | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06397768 Background | May 2024 → Sep 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT06314724 Comparator | Feb → Sep 2024 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04016714 Background | Aug 2019 → Oct 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT03620162 Background | Oct 2018 → Dec 2020 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03691610 Background | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03673462 Background | Sep 2018 → Mar 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03239873 Comparator | Oct 2017 → Aug 2018 | chickenpox | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03114943 Comparator | Jul 2016 → Jun 2017 | chickenpox | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01702428 Background | Nov 2012 → Nov 2014 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01681992 Background | Oct 2012 → Feb 2015 | measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | Mixed |
| Phase 3 | NCT01505647 Comparator | Apr → Jul 2012 | herpes zoster | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01439360 Comparator | Oct 2011 → Oct 2014 | influenza | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01346293 Background | Apr 2011 → May 2013 | diphtheria, measles, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00822237 Comparator | Jan → Oct 2009 | chickenpox | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00839917 Comparator | Feb → May 2008 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00345683 Background | Jul 2007 → Sep 2008 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00289783 Background | Feb 2006 → Aug 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00985166 Comparator | Aug 2000 → May 2002 | measles, mumps infectious disease, rubella, varicella zoster infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00984295 Comparator | Jun 2000 → Oct 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00985153 Comparator | Mar 2000 → May 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00975507 Comparator | Mar 1998 → Jan 1999 | measles, mumps infectious disease, rubella, varicella zoster infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | GlaxoSmithKline | Results GSK presents new data at the Alzheimer's Association International Conference 2024 gsk.com ↗
Retrospective study observed statistically significant association between Shingrix vaccination and reduction of dementia risk, compared to Zostavax and Pneumovax 23, with further studies planned |
| 2023-03-06 | Merck Sharp & Dohme LLC | Regulatory US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗
With these approvals, healthcare professionals now have the option to choose to administer all routinely recommended injectable pediatric vaccinations included in the CDC immunization schedule, via the same IM route. |
| 2023-01-09 | SK Bioscience Co., Ltd. | Regulatory SK bioscience’s Shingles Vaccine Receives Biologics License Application Approval in Malaysia skbioscience.com ↗
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, announced that the company has received a biologics license application approval of the ‘SKYZoster’ from the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia. |
| 2018-02-09 | Merck Sharp & Dohme LLC | Regulatory VARIVAX, Merck’s Varicella (Chickenpox) Vaccine, Awarded WHO Pre-Qualification Status merck.com ↗
VARIVAX ® (varicella virus vaccine live), the live attenuated varicella-zoster (VZV) vaccine from Merck & Co., Inc (known as MSD outside the U.S. and Canada) that helps prevent varicella (chickenpox) in individuals 12 months of age and older, has been awarded pre-qualification status by the World Health Organization (WHO). |
| 2013-10-28 | Merck Sharp & Dohme LLC | Regulatory Merck Announces Third-Quarter 2013 Financial Results merck.com ↗
Received approval from the FDA to manufacture bulk varicella at the company’s site in Durham, N.C., for use in Merck’s vaccines to protect against chickenpox and shingles. |
| 2013-09-04 | Merck Sharp & Dohme LLC | Regulatory Merck’s Durham Site Receives U.S. FDA Licensure for Varicella Bulk merck.com ↗
The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Merck’s overall global supply capabilities. |
All press releases naming this drug 12 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 69 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VARIVAX | “A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and...” NCT06855160 ↗43“All participants will be randomized to receive either one dose each of DTap-IPV + Measles, Mumps, and Rubella Virus Vaccine Live (M-M-R®II) + VARIVAX® or one dose each of...” NCT01346293 ↗ “GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine...” NCT00197015 ↗ “varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II).” PMID 32429738 ↗ May 2020 “Varivax is a vaccine against varicella zoster virus (VZV), the virus that causes chickenpox (varicella) and shingles (zoster).” NCT00000837 ↗ “compared to the licensed varicella vaccine, Varivax (VV), as a first dose for children aged 12 to 15 months in the US.” NCT05084508 ↗ “M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age” NCT03673462 ↗ “Live, attenuated varicella vaccine, Varivax” NCT00505063 ↗ |
| Known as | HPV vaccine, Merck | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04774887 ↗ |
| Known as | Live, attenuated varicella vaccine, Varivax | “Live, attenuated varicella vaccine, Varivax” NCT00505063 ↗ |
| Known as | ProVarivax | “subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).” NCT01439360 ↗ |
| Known as | Varicella Virus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673462 ↗ |
| Known as | Varicella Virus Vaccine Live | “VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension” NCT03843632 ↗ |
| Known as | Varicella Virus Vaccine Live (1999 Process) (Oka/Merck) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822237 ↗ |
| Known as | Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822237 ↗ |
| Known as | Varicella Virus Vaccine Live [Oka/Merck] | “Participants aged 12 months-12 years were administered 1 dose of VARIVAX™ 0.5 mL (Varicella Virus Vaccine Live [Oka/Merck]) and adolescents aged 13-17 years were administered 2...” PMID 34702124 ↗ Oct 2021 |
| Known as | Varicella Zoster Virus Vaccine Live (Oka/Merck) | “Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older” NCT00092417 ↗ |
| Known as | ZOSTAVAX | “Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process” NCT01505647 ↗1“zoster vaccine live (ZOSTAVAX™)” NCT00322231 ↗ |
| Known as | zoster vaccine | “One dose of zoster vaccine (ZV) has demonstrated substantial protection against HZ” PMID 22154769 ↗ Dec 2011 |
| Known as | zoster vaccine live | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00322231 ↗ |
| Known as | zoster vaccine live (Oka/Merck) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00109122 ↗ |
| Known as | Zoster Vaccine, Live (AMP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01505647 ↗ |
| Known as | ZVL | “Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time.” PMID 30165651 ↗ Jan 2019 |
| Modality | Vaccine | “Varivax is a vaccine” NCT00000837 ↗ |
| Route | Subcutaneous | “0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).” NCT00005009 ↗ |